ניקסואה מכריזה על תוצאות ראשוניות לרבעון השני של 2026

המשך המומנטום בהשקה בארה"ב מוביל להכנסות נטו גלובליות ראשוניות של 7.7 מיליון אירו ברבעון השני.

מונט-סן-גיבר, בלגיה – 7 ביולי 2026, GLOBE NEWSWIRE –

Nyxoah SA (נאסד"ק/יורונקסט בריסל: NYXH), חברת טכנולוגיות רפואיות המתמקדת בפיתוח פתרונות חדשניים לטיפול בדום נשימה חסימתי בשינה (OSA), באמצעות נוירומודולציה, דיווחה היום על תוצאות פיננסיות ותפעוליות ראשוניות ולא מבוקרות לרבעון השני של 2026.

Nyxoah Announces Preliminary Results for the Second Quarter of 2026

Continued U.S. launch momentum drives second quarter global preliminary net revenue of €7.7 million
CMS proposes 2027 OPPS and ASC payment increase of 12% and 15% respectively

Mont-Saint-Guibert, Belgium – July 7, 2026, GLOBE NEWSWIRE –

Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today reported certain preliminary unaudited second quarter 2026 financial and operating results.

Second Quarter 2026 – Preliminary Sales and Market Metrics

• Financials
  • Global net revenue is expected to beapproximately €7.7 million in the second quarter of 2026, which reflects21% sequential growth over the first quarter of 2026
  • U.S. net revenue is expected to beapproximately €5.2 million in the second quarter of 2026, which reflects22% sequential growth over the first quarter of 2026
• Leading U.S. commercial indicators
  • 55 new surgeons trained in Q2, bringing thetotal to 262 surgeons trained
  • 89 new accounts activated in Q2, bringing thetotal to 180 active high-volume accounts
  • 427 patients submitted under priorauthorization entering Q3
• Reimbursement US
  • CMS is proposing to increase hospitalreimbursement for the Genio procedure (C8011) from $31,526 to $35,414,representing an increase of $3,888 (12%)
  • CMS is proposing to increase ASCreimbursement from $27,563 to $31,722, an increase of $4,159 (15%)
• Liquidity
  • $110 million in aggregate financing securedin Q2
  • As of June 30, 2026,cash, cash equivalents and financial assets are expected to beapproximately €97.8 million

"We closed Q2 with clear U.S. momentum: the scaling of our U.S. sales force allowed us to double the number of active accounts to 180 high-volume HGNS accounts and deliver a second consecutive quarter of over 20% sequential U.S. revenue growth. Additionally, the recent CMS proposed reimbursement increases in both hospital outpatient and ambulatory surgical centers are among the strongest within APC 5465 (Level 5 Neuromodulation) and, if approved, support continued economic value for the Genio procedure,” commented Olivier Taelman, Nyxoah's Chief Executive Officer. “With $110 million in new financing, the financial overhang is now behind us, and we are positioned to accelerate Genio's U.S. commercial ramp and drive toward profitability."

Revenue Guidance for the Full Year 2026

• The Company continues to expect globalnet revenue for the full year 2026 to be in the range of €36 million to€40 million.

The preliminary, unaudited revenue results and cash, cash equivalents and financial assets described in this press release are estimates only and are subject to revision until Nyxoah reports its full financial results for the second quarter of 2026, including in its Quarterly Report on Form 6-F.

Upcoming Investor and Analyst Day

The Company will be hosting an Investor and Analyst Day on Wednesday, July 8, 2026, in New York. The event will be held at the offices of Bank of America and will run from 10:00 AM to 12:30 PM ET (16:00 to 18:30 CET).

The event will be webcast live for those unable to attend in person, with a replay available shortly afterwards. Participants joining via the webcast will be able to ask questions during the event.

Event details

• Date: Wednesday, July8, 2026
• Time: 10:00 AM to12:30 PM ET (16:00 to 18:30 CET)
• Location: Bank ofAmerica Tower at One Bryant Park, 1111 Avenue of the Americas, NewYork, NY
• Registration andwebcast access:

https://www.netroadshow.com/events/login/1PeTHmohOsvcptHhJ0ULn0T429N8JKb3IuZtL

About Nyxoah

Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat OSA. Nyxoah’s lead solution is the Genio system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.

Following the successful completion of the BLAST OSA study, the Genio system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company announced positive outcomes from the DREAM IDE pivotal study and receipt of approval from the FDA for a subset of adult patients with moderate to severe OSA with an AHI of greater than or equal to 15 and less than or equal to 65.

For more information, please visit http://www.nyxoah.com/.

Caution – CE marked since 2019. FDA approved in August 2025 as prescription-only device.

Contacts:

Nyxoah
John Landry, CFO
[email protected]

Rémi Renard
Head of Investor Relations & Corporate Communication
[email protected]

Attachment

• ENGLISH_Nyxoah Prelim Earnings PRQ2

*** הידיעה מופצת בעולם על ידי חברת התקשורת הבינלאומית GlobeNewswire